Concentration-and time-dependent effects of two antiepileptic drugs (AEDs), levetiracetam (LEV) and valproic acid (VPA), on proliferation, cytotoxicity and expression of cell cycle regulatory genes were investigated in a human ovarian cancer cell line, OVCAR-3. Cells were cultured with VPA or LEV, at concentrations between 100 µM and 10 mM. Cell proliferation was determined by alamarBlue and BrdU incorporation assays; cytotoxic effects by tetrazolium hydroxide (XTT), acid phosphatase (AP) and lactate dehydrogenase (LDH) assays. Expression of cell cycle regulatory genes was determined by real-time PCR. Exposure to VPA caused a concentration-and time-dependent decrease in cell proliferation (alamarBlue and BrdU incorporation assays), cytotoxic effects above 2.5 mM (XTT and AP assays) and modulated expression of genes primarily responsible for cell cycle arrest in G phase. Cell proliferation was unaffected by exposure to LEV for 24 h and 120 h (alamarBlue assay), but increased when exposed to LEV for 72 h and 168 h, at concentrations from 250 µM to 1 mM. The BrdU incorporation assay showed no effect of LEV on cell proliferation. LEV was cytotoxic at higher concentrations (AP assay), but modulation in expression of cell cycle regulatory genes was not observed. Changes in LDH release were not observed with either AED. In summary, VPA apparently decreased cell proliferation by down-regulating genes responsible for transition from G to S phase and up-regulating genes responsible for G phase arrest, which suggest its potential as an anticancer drug. LEV does not exhibit such action.
Introduction
Epithelial ovarian cancer is the most lethal of gynecologic malignancies and current therapeutic regimens for ovarian cancer are largely ineffective in terms of long-term treatment [15] . Thus, development of improved, alternative therapy strategies against ovarian cancer is an important health priority.
It has recently become evident that several antiepileptic drugs (AEDs) are associated with anticancer activity and have influence on cell growth in several cancer cell types in vitro [2] . Valproic acid (VPA) is one of the most frequently prescribed antiepileptic drugs in the world, while levetiracetam (LEV) is a relatively new AED that has been extensively used in recent years [8] . Accumulating evidence indicates that VPA is associated with anticancer activity, by inducing differentiation, growth arrest and/or apoptosis in many tumor cells [for review see ref . 3] . Recently, antitumor activity of VPA was also suggested in ovarian cancer cells. Takai et al. [31] showed that VPA causes growth inhibition, cell cycle arrest, apoptosis induction and alterations in the expression of genes in nine ovarian cancer cell lines. Furthermore, VPA has been shown to interact with standard anticancer drugs, resulting in increased inhibition of ovarian cancer development both in vivo [5] and in vitro [19] . To our knowledge, there is one report suggesting antitumor effects of LEV in glioblastoma cells [4] . These authors showed that LEV inhibited cell proliferation and decreased expression of genes and proteins responsible for tumor cell resistance.
Considering these reports, we decided in current study to compare the concentration-dependent and time-dependent effects of VPA and LEV on proliferation, viability and expression of genes important in cell cycle regulation, using a human ovarian cancer cell line, OVCAR-3, as a model system.
Materials and Methods

Reagents
RPMI1640 medium without phenol red, fetal bovine serum (FBS, heat inactivated), penicillin/streptomycin solution (penicillin 10,000 units/ml, streptomycin 10 mg/ml), phosphate-buffered saline (PBS) and trypsin + EDTA were obtained from Cytogen GmbH (Bienenweg, Germany). VPA was obtained from Sigma Chemical Co. (St. Louis, MO, USA) and dissolved in sterile water. LEV was purchased from UCB Pharma, Belgium (Keppra 100 mg/ml®, for intravenous infusion). The solutions were then further diluted in culture medium.
Cell culture
The human ovarian epithelial carcinoma cell line, OVCAR-3, was obtained from American Type Culture Collection (Manassas, VA, USA). Cells were routinely cultured in RPMI1640 medium without phenol red, supplemented with 20% heat-inactivated FBS, 50 IU/ml of penicillin and 50 µg/ml of streptomycin. The medium was changed every two days. Cells were grown in 75 cm 2 culture flasks in a 37°C incubator with a humidified mixture of 5% CO 2 and 95% air. For individual experiments, cells were cultured in RPMI 1640 without phenol red supplemented with 5% heat inactivated FBS.
AlamarBlue assay
Long-term cell proliferation was determined using an alamarBlue assay (Invitrogen, Carlsbad, CA, USA). This assay is designed to quantify the proliferation of various human cell lines and is based on detection of the cells' metabolic activity (reduction of resazurin). AlamarBlue has minimal cell toxicity and therefore is appropriate for continuous monitoring of proliferation in the same cell culture at various time points. Cells were seeded into 96-well culture plates at a density of 1.5 × 10
" cells/well and allowed to attach overnight. The next day, the medium was changed and cells were treated with VPA or LEV at concentrations ranging from 100 µM to 10 mM for 24, 72, 120 and 168 h. Culture medium was used as a control. Medium was changed daily, with new medium and new test compounds added. The alamarBlue stock solution was aseptically added to the wells after 24, 72, 120 and 168 h of culture, in amounts equal to 10% of incubation volume. Resazurin reduction was determined after 4 h incubation by measuring the absorbance at 570 nm using a fluorescence microplate reader FLx800 (BioTek, Winooski, VT, USA). Six replicates of each sample were run in the same assay.
BrdU incorporation assay
DNA synthesis in proliferating cells was determined by measuring bromodeoxyuridine (BrdU) incorporation using the commercial Cell Proliferation ELISA System (Roche Molecular Biochemicals, Mannheim, Germany). In this assay, BrdU is incorporated into DNA during S phase.
Cells were seeded into 96-well culture plates at a density of 1.5 × 10 " cells/well and allowed to attach overnight. The next day, the medium was changed and cells were treated with VPA or LEV at concentrations ranging from 100 µM to 10 mM for 72 h. Culture medium was used as a control. Medium was changed daily, with new medium and new test compounds added. After 72 h incubation, the medium was removed and the cells incubated for 3 h with a BrdU labelling solution (provided with the kit), containing 10 µM BrdU. The BrdU incorporation assay was performed according to the manufacturer's instructions. Absorbance values were measured at 450 nm using an absorbance microplate reader ELx808 (BioTek, Winooski, VT, USA). Culture medium alone was used as a control for nonspecific binding. Six replicates of each sample were run in the same assay.
Cytotoxicity assays
We performed three independent cytotoxicity assays to investigate alterations in metabolic pathways or structural integrity induced by exposure to VPA or LEV.
Cells were seeded into 96-well culture plates at a density of 1 × 10 " cells/well and allowed to attach overnight. After 24 h, the medium was changed and cells were treated with VPA or LEV at concentrations ranging from 100 µM to 10 mM for 72 h. Culture medium was used as a control. Medium was changed daily, with new medium and new test compounds added.
XTT cell viability assay
The XTT sodium salt [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt] assay was used to measure the viability of cells. Tetrazolium salts are reduced to formazan by mitochondrial succinate dehydrogenase, an enzyme that is only active in cells with an intact metabolism and respiratory chain. The formazan can be quantified photometrically and correlates with the metabolic activity and number of viable cells.
The XTT assay (Xenometrix, Allschwil, Switzerland) was performed according to the manufacturer's instructions, after 72 h incubation with LEV or VPA. The XTT reduction in the cultures was determined after 2 h incubation by measuring the absorbance at 450 nm using an absorbance microplate reader ELx808 (BioTek, Winooski, VT, USA). All samples were run in triplicate in the same assay.
Acid phosphatase (AP) assay
AP is a functional marker of lysosomal metabolism. Enzyme activity is determined by measuring the conversion of p-nitrophenylphosphate (pNPP) to p-nitrophenolate (pNP) and correlates with viable cell number.
The AP assay (Xenometrix, Allschwil, Switzerland) was performed according to the manufacturer's instructions, after 72 h incubation with LEV or VPA. The activity of AP in the cultures was determined after 2 h incubation by measuring the absorbance at 405 nm using an absorbance microplate reader ELx808 (BioTek, Winooski, VT, USA). All samples were run in triplicate in the same assay.
Lactate dehydrogenase (LDH) assay
The LDH assay was used to check membrane integrity in cells exposed to LEV or VPA. LDH is rapidly released from damaged cells into cell culture supernatant, where it oxidizes NADH to NAD + . NADH consumption in the supernatant correlates with the amount of LDH released. Cell viability is inversely proportional to the amount of LDH released.
The LDH assay (Xenometrix, Allschwil, Switzerland) was performed according to the manufacturer's instructions, after 72 h incubation with LEV or VPA. NADH oxidation was determined by measuring the decrease in absorbance at 340 nm using an absorbance microplate reader ELx808 (BioTek, Winooski, VT, USA). All samples were run in triplicate in the same assay.
Real-time PCR analysis
Cells were seeded into 96-well culture plates at a density of 2 × 10 4 cells/well. The next day, the medium was changed and cells were treated with 5 mM VPA or 10 mM LEV (concentrations selected on the basis of alamarBlue, BrdU and cytotoxicity assays) for 24 h. Total RNA isolation and cDNA synthesis was performed using the TaqMan Gene Expression Cellto-C T Kit (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer's protocol. The purity and quantity of the RNA and cDNA were determined by spectrophotometry at optical densities 260 nm and 280 nm. 
Statistical analysis
Each experiment was repeated three times (n = 3). All results were expressed as the means ± standard error of the mean (SEM). Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software Inc., CA, USA). Data were analyzed by one-way analysis of variance, followed by Tukey's Honestly Significant Difference multiple range test. Groups that are significantly different from control are indicated in the figures as: * p < 0.05, ** p < 0.01, *** p < 0.001.
Results
Determination of long-term cell proliferation using the alamarBlue assay
In an initial approach to analyze the effects of VPA and LEV, we performed a long-term alamarBlue assay, to determine the concentration-dependent and time-dependent action of LEV and VPA on ovarian cancer cells OVCAR-3. In the control culture, proliferation increased from 14,000 ± 850 relative fluorescence units at 24 h to 22,000 ± 1,300 relative fluorescence units at 168 h of culture. Cell proliferation at 24 h of culture was the same for cells exposed to VPA as for control, while a decrease in cell proliferation was noted in cells exposed to VPA con-
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Pharmacological centrations from 2.5 mM at 72 h, from 1 mM at 120 h and from 750 µM at 168 h of incubation (Fig. 1a) . In LEV-exposed cells, no differences in proliferation from control cells were noted at 24 h and 120 h of incubation. However, after 72 h and 168 h in culture, cells exposed to LEV concentrations ranging from 250 µM to 1 mM demonstrated an increase in proliferation (Fig. 1b) .
Determination of cell proliferation using the BrdU incorporation assay
A significant inhibitory effect of VPA on cell proliferation was noted at concentrations from 2.5 mM to 10 mM (Fig. 2a) . Exposure to LEV at all concentrations used did not have any effect compared with the control (Fig. 2b) .
Determination of cytotoxic effects
According to the XTT and AP assays results, exposure to VPA at concentrations from 2.5 mM resulted in significant cytotoxic effects (Fig. 3a, 3b ), but no significant changes in LDH release into the culture medium (Fig. 3c) .
Although exposure to LEV at concentrations from 250 µM to 7.5 mM caused an increase reduction of XTT (Fig. 4a) , according to the AP assay, cytotoxic effects occurred following exposure to LEV at conPharmacological Reports, 2012, 64, 157165 161
Effects of VPA and LEV on OVCAR-3 cell line viability
Patrycja Kwieciñska et al. centrations from 7.5 mM (Fig. 4b) . As with VPA, LDH levels were not observed to be affected by LEV exposure at all concentrations used (Fig. 4c) .
Measurement of expression of cell cycle regulatory genes by real-time PCR analysis
The relative expression of selected genes involved in cell cycle regulation are described in Table 1 . Exposure of cells to VPA resulted in down-regulation of the following genes: CCNA1, CCND3, CCNE1, CCNE2, CCNH (cyclin genes), CDK2, CDK7 (cyclin-dependent kinase genes), CDC25A (CDC25A phosphatase gene), E2F4 (transcription factor E2F4 gene). Parallel up-regulation was observed for: TP53 (tumor protein p53 gene), CDKN1A and CDKN2A (cyclin-dependent kinase inhibitors genes). All these genes are involved in arrest of the cell cycle in G 1 phase. Exposure to LEV apparently had no effect on the expression of any of these genes involved in cell cycle regulation.
Discussion
The results from the present study show that exposure to VPA decreases cell proliferation in a concentrationand time-dependent manner, as demonstrated by both alamarBlue and BrdU incorporation assays. These data concur with results published by Takai et al. [31] , who also demonstrated growth inhibition of OVCAR-3 cells under the influence of VPA. Additionally, VPA has been shown to interact with standard anticancer drugs, resulting in increased inhibition of ovarian cancer development both in vivo [5] and in vitro [19] . The results from the viability assays in this study demonstrated a significant cytotoxic effect of VPA above 2.5 mM, as shown by the XTT and AP assays and no effect on LDH release from cells. The AP assay is used to quantify the lysosomal metabolism of cells in response to pharmaceutical, chemical and environmental compounds, like XTT assay, which is used to measure the mitochondrial metabolism of cells. The results from the XTT and AP assays in combination clearly suggest that VPA causes cytotoxic effects in OVCAR-3 cells. Following the demonstration that VPA decreased OVCAR-3 cells proliferation and acts as cytotoxic drug, it was pertinent to examine the underlying mechanisms that cause this anti-proliferative effect. The investigation of expression of genes involved in cell cycle regulation showed that VPA had most affect on the expression of CDKN1A and CDKN2A genes, which encode the cyclin-dependent kinase inhibitor p21 and cyclin-dependent kinase inhibitor p16, respectively, and are primarily linked to G -phase regulation. It is noteworthy that regulators of cell cycle machinery are frequently altered in human cancers and can be more sensitive to cyclin-dependent kinases' inhibition [28] . Moreover, altered expression of multiple genes and proteins involved in cell cycle regulation (especially p21 and p16), has previously been reported in cancer cells exposed to VPA treatment [6, 7, 9, 10, 16, 17, 22, [30] [31] [32] 34] . In addition, we showed that VPA stimulated TP53 transcription. Tumor protein p53 is known to be induced as a result of DNA fragmentation; activation of p53 results in G arrest by inducing p21, followed by an inhibition of cyclin/Cdk complex [18] . Marked inhibition in expression of other genes involved in cell cycle regulation, which encode both cyclins (cyclin A, cyclin E, cyclin D, cyclin H) and cycline-dependent kinases (Cdk2 and Cdk7), was also observed. These proteins form cyclin/Cdk complexes and regulate progression of the cell cycle through specific checkpoints [20] . Cyclin E/Cdk2 is required for S phase entry, cyclin A/Cdk2 for S phase progression and D cyclins, associated with Cdk4 and Cdk6, are required for progression of cells through G into S phase. Furthermore, cyclin H/Cdk7 complex and phosphatase Cdc25A are [26] demonstrated that LEV did not affect the number of BrdUpositive cells in rat hippocampus. Surprisingly, exposure to LEV increased cell proliferation measured by alamarBlue assay and activity of mitochondrial enzymes, as measured with the XTT assay. It could be explained by the fact that both assays determine total cell number by detection of cellular (mitochondrial) metabolic activity. Additionally, a cytotoxic effect of LEV (AP assay) was noted only at higher concentrations and no change in LDH level was observed. AP is a functional marker of the lysosomal compartment [14] and the lysosomal enzymes are known to initiate cell death [12] , but it is also suggested that activation of lysosomal enzymes is specific for tumor regression, but do not affect proliferation [1] . Although the effects of VPA on cancer growth are widely known, only limited data on the effect of LEV on cellular proliferation are available. Whilst data indicating that LEV has a very positive effect on brain tumorassociated seizures have been published, whether the development of cancer per se is affected by LEV is unknown [21, 23-25, 29, 35] . Indeed, it has been demonstrated that LEV does not interact with chemotherapies used in the treatment of brain tumors [27] .
In contrast to VPA, the expression of cell cycle genes appeared to be unaffected by exposure to LEV. Data published by Hassel et al. [13] reported regionspecific gene expression as a result of LEV treatment, but as LEV-induced regional changes in gene expression were not closely associated with the distribution of known LEV binding sites (such as synaptic vesicle protein SV2A), no plausible explanation could be provided. Additionally, other research has shown that LEV does not modify gene expression in nonepileptic rat brain [11] , nor in brains of non-epileptic newborn mice [33] .
Taken together, these results suggest that LEV disrupts cells metabolism, but this has no effect on cell proliferation and cell cycle regulating genes expression.
In conclusion, the results of this preliminary study, suggest that VPA, but not LEV, may have potential as an anticancer drug for human ovarian cancer treatment due to its cytotoxic and cytostatic activities. However, further studies, based on apoptotic mechanisms, are essential to confirm this suggestion.
